A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa

Last updated: February 14, 2025
Sponsor: GlaxoSmithKline
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Whole blood sample

Clinical Study ID

NCT03855995
115056
  • Ages < 5
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The RTS, S/AS01E vaccine was developed to protect children in sub-Saharan Africa from malaria as part of routine immunization programs. This study aims to check the vaccine's safety after it has been introduced. Along with safety, researchers will also assess how well the vaccine works and its overall impact on children's health.

Eligibility Criteria

Inclusion

Inclusion Criteria

All study participants must satisfy ALL the following criteria at study entry:

  • Study participants' parent(s)/ LAR(s) who, in the opinion of the investigator, canand will comply with the requirements of the protocol.

  • Written informed consent provided from either the parent(s) or LAR of the studyparticipant.

  • Study participant living in the HDSS or equivalent surveillance system area.

  • For enrolment in the active surveillance - DTP group: children must be aged lessthan (<) 18 months, identified at any administration of DTP/HepB/Hib (or athospitalisation before 3rd dose of DTP/HepB/Hib in case of hospitalisation andvaccinated with at least one dose of DTP/HepB/Hib). (This group will includechildren from exposed and unexposed clusters.) OR For enrolment in the activesurveillance - Catch-up group: children must be aged <18 months, received at leastone dose of DTP/HepB/Hib vaccine, whose age corresponds to the age after the 3rddose of DTP/HepB/Hib vaccine, (=who either received all DTP/HepB/Hib doses beforestudy start or received at least one dose of DTP/HepB/Hib and are older than the agecorresponding to the 3rd DTP/HepB/Hib dose at study start) and identified at 1stRTS,S/AS01E dose administration (This group will include children from exposedclusters only).

OR For enrolment in the enhanced hospitalisation surveillance: children must be aged at least 6 weeks and <5 years at the time of hospitalisation at any time during the study. (This group will include children from exposed and unexposed clusters.) Parents/LARs of children meeting all eligibility criteria for active surveillance, not having completed the visits for DTP/HepB/Hib, and first identified during hospitalisation, must first be proposed enrolment in active surveillance (if recruitment is not completed).

Children already enrolled in active surveillance will have hospitalization monitored as part of the procedures related to the active surveillance and can therefore not be enrolled in enhanced hospitalization surveillance.

Exclusion

Exclusion Criteria:

• Child in care = A child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government, or a government body, acting in accordance with powers conferred on them by law or regulation. The definition of a child in care can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a child in care does not include a child who is adopted or has an appointed legal guardian.

Study Design

Total Participants: 78000
Treatment Group(s): 1
Primary Treatment: Whole blood sample
Phase:
Study Start date:
March 21, 2019
Estimated Completion Date:
May 26, 2025

Study Description

This is a disease surveillance study with prospective cohort event monitoring including both temporal and concurrent comparisons of the occurrence of adverse and malaria events between vaccinated and unvaccinated subjects living in exposed or unexposed clusters located in sub-Saharan Africa (SSA) countries, and eligible for RTS,S/AS01E vaccination for those living in the exposed clusters. The design includes active surveillance and enhanced hospitalization surveillance in both exposed and unexposed clusters.

The study targeted enrolling at least 45,000 children in active surveillance, including 22,500 in the exposed clusters and 22,500 in the unexposed clusters for evaluation of the vaccine safety, effectiveness, and impact.

All data analyses will be computed in a descriptive manner. Data regarding the hospitalization will be uniformly collected whether the child is enrolled in active surveillance or in enhanced hospitalization surveillance.

Connect with a study center

  • GSK Investigational Site

    Kintampo,
    Ghana

    Active - Recruiting

  • GSK Investigational Site

    Navrongo,
    Ghana

    Active - Recruiting

  • GSK Investigational Site

    Kisumu, 4 0100
    Kenya

    Active - Recruiting

  • GSK Investigational Site

    Blantyre,
    Malawi

    Site Not Available

  • GSK Investigational Site

    Chikwawa,
    Malawi

    Active - Recruiting

  • GSK Investigational Site

    Mangochi,
    Malawi

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.